Operator Welcome to the Bristol Myers Squibb fourth quarter 2024 earnings conference call. [Operator instructions] Please note this event is being recorded. I would now like to turn the conference ...

Around the same time, the prototype of the Squibb logo was designed. The logo represented product uniformity, purity, efficacy and reliability based on research. By 1924, Bristol-Myers' gross ...

Welcome to the Bristol-Myers Squibb Fourth Quarter 2024 Earnings ... That's what we're focused on, and that's what we're going to be transparent about our performance against on these calls.

This was the stock's second consecutive day of losses.

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

This was the stock's third consecutive day of losses.

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...

The quarter's results, reaffirmed Bristol Myers Squibb's financial health and strategic focus despite ongoing competition from generics manufacturers impacting its legacy portfolio of drugs.